What it is
A simple explanation of IGF-LR3 and why it is commonly studied in peptide research.


IGF-1 LR3 is a modified long-acting analog of Insulin-like Growth Factor 1 — engineered with an Arg3 substitution and a 13-amino-acid N-terminal extension that drastically reduces binding to IGF-binding proteins. The result is a growth-factor signal that stays active in circulation 20–30x longer than native IGF-1, drives protein synthesis, partitions nutrients toward lean tissue, and supports the recovery environment behind serious physique work.
A quick, simple breakdown of what IGF-LR3 is, why researchers study it, how it works, and what makes it unique.
A simple explanation of IGF-LR3 and why it is commonly studied in peptide research.
A clear breakdown of the mechanisms, pathways, and research areas connected to IGF-LR3.
A high-level overview of why researchers explore IGF-LR3 in recovery, tissue, and systemic models.
Designed to help visitors understand the product before exploring the full research guide.
Think of IGF-1 LR3 as a long-acting growth-factor signal — the downstream effector of the GH axis, working directly on the tissue level rather than relying on the body's natural pulse.
Native IGF-1 binds IGFBPs within minutes and gets cleared. The LR3 modification keeps the molecule active in circulation for 20–30 hours, allowing one daily injection to maintain steady growth-factor signaling at the tissue level.
It's a serious, advanced compound — not a beginner-level peptide. It belongs in the conversation when the training, nutrition, and discipline are already locked and the next layer of body-composition progress is the goal.
"Think of IGF-1 LR3 as the construction manager that decides whether nutrients build new tissue or get stored — when the signal is loud, the build favors lean mass."
It doesn't replace training or nutrition. It amplifies the growth-factor signal that determines how effectively your body converts hard work into lean tissue and recovery.
Past your mid-20s, IGF-1 declines steadily — and with it, the speed at which training, food, and recovery translate into visible physique progress.
Same hard sessions. Same clean food. Less return. As growth-factor signaling weakens, the link between effort and adaptation thins out.
You can still push hard — but the bounce-back falls behind the work. Soreness lingers. Sessions back-to-back stop stacking the way they used to.
Without strong growth-factor signaling, more calories drift toward storage and fewer feed lean tissue and recovery.
Pumps shorten. Visual fullness fades. The 'three-dimensional' look that comes from active growth-factor signaling softens into something flatter.
Subcutaneous IGF-1 LR3 enters circulation and binds IGF-1 receptors directly with extended duration.
IGF-1 LR3 binds IGF-1 receptors on muscle, tendon, and other tissues — activating the same downstream pathways as native IGF-1 but with vastly extended duration.
Supports glucose uptake and amino acid utilization, pushing nutrients toward performance, recovery, and lean tissue rather than storage.
Drives the growth-and-repair environment that turns hard training into real body-composition progress — fuller tissue, cleaner recovery, sharper output.
Downstream effects of restoring strong growth-factor signaling in trained, well-fed athletes.
Protein synthesis pathways stay activated longer. Tissue-level growth-factor tone climbs.
More glucose and amino acids feed lean tissue and recovery, less drifts to storage.
Three-dimensional fullness returns. Pumps last longer. Visual density climbs.
The growth-and-repair environment stays elevated between sessions.
IGF-1 receptors are dense in connective tissue. Tendons remodel better under load.
Consistent recovery means consistent training. Volume climbs without breakdown.
Over a clean run, the ratio of lean to non-lean tissue meaningfully improves.
The kind of progress that compounds when the basics are already locked.
The lived signals — week by week — as long-acting growth-factor signaling stabilizes.
Fuller muscle feel, better pump, stronger nutrient-use awareness post-meal.
Recovery between sessions tightens. Volume tolerance climbs. Visible fullness improves.
Body composition shifts visibly. Training output stabilizes at a higher baseline.
Leaner, fuller look. Deeper growth-and-recovery signaling. The new physique baseline holds.
Exact measurements based on 1 mg vial + 1 mL bacteriostatic water.
Change any input. Every value below updates automatically from the formula. No guessing.
Units, weeks per vial, and vials per cycle — all derived from your 1 mg vial + 1 mL BAC water.
Daily injections, preferably post-workout on training days and morning on rest days. Rotate sites across abdomen.
Short 4-week cycles with 4 weeks off preserve receptor sensitivity. Continuous use downregulates response quickly.
Based on the Standard tier: 40 mcg × 5/week = 0.20 mg per week. One 1 mg vial lasts approximately 5 weeks.
One vial may not cover a full standard cycle. Use the standard-cycle supply option to complete the full protocol without interruption.
Educational context only. This is not a guarantee of outcomes.
IGF-1 LR3 amplifies the growth-factor signal. Paired with the right co-signals, the entire growth, recovery, and repair stack runs in concert.
CJC/Ipa fires the GH pulse; IGF-1 LR3 is the downstream messenger. Complete anabolic axis.
IGF-1 LR3 drives anabolism; BPC-157 targets specific injuries. Recovery + growth.
IGF-1 LR3 can affect insulin sensitivity. MOTS-c keeps the metabolic side clean.
IGF-1 LR3 is a long-acting analog of Insulin-like Growth Factor 1, engineered to remain active in circulation 20–30x longer than native IGF-1. It binds IGF-1 receptors directly to support protein synthesis, nutrient partitioning, lean tissue signaling, and recovery.
Most researchers report fuller muscle feel and better pump within 1–2 weeks. Body-composition and recovery shifts typically emerge over 4–6 weeks of consistent use paired with disciplined training and nutrition.
Standard: 40 mcg subcutaneously once daily, post-workout on training days. Cycle 4–6 weeks on followed by 4–6 weeks off to preserve receptor sensitivity. This is an advanced compound; respect the cycle structure.
Possible side effects: hypoglycemia (always dose with food), injection-site lumps, joint stiffness, headache. Not appropriate for individuals with active cancer or untreated diabetes. Consult a clinician before use.
Every batch of our IGF-1 LR3 is independently third-party tested for purity (>99%), peptide identity via HPLC and mass spectrometry, and endotoxin levels. A Certificate of Analysis is available for the exact lot you receive. We ship from a temperature-controlled facility in San Diego — IGF-1 LR3 in particular demands cold-chain handling, which we never compromise on.
IGF-1 declines steadily past your mid-20s. The flatter look and slower recovery that follow aren't lack of effort — they're a fading signal at the tissue level.
Research-grade IGF-1 LR3, 1 mg per vial. Third-party tested. Cold-chain handled. For serious physique work only.
Explore IGF-1 LR3Source IGF-LR3 from Blueprint Peak Performance — third-party tested for >99% purity, cold-chain handled, shipped from San Diego. Educational research use only.
Blueprint Research Guide is editorial. The link above sources research-grade compounds from Blueprint Peak Performance — an independent supplier. For educational purposes only. Research use only — not for human consumption, treatment, or diagnosis.